BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 





 Company News
Bristol-Myers Squibb (BMY) Release: Study Of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results In Preventing Viral Replication Via Different Mechanism Of Action Than Current Therapies 2/26/2015 11:17:38 AM
Regen BioPharma Comments On Dcellvax Cancer IDO-Targeting Technology In Relation To Bristol-Myers Squibb (BMY)-Flexus Biosciences Announcement 2/25/2015 1:54:57 PM
Bristol-Myers Squibb (BMY) Release: 48-Week Analysis Of Investigational HIV-1 Attachment Inhibitor Paves Way For Phase III Trial Initiation 2/25/2015 10:40:35 AM
Jacobs Awarded Contract From Bristol-Myers Squibb (BMY) 2/24/2015 12:28:39 PM
Bristol-Myers Squibb (BMY)To Present At Cowen and Company Annual Global Health Care Conference 2/24/2015 11:17:22 AM
Bristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1.74M Grant To Address Lung Cancer Among Neediest Communities In Central Savannah River Area 2/23/2015 10:30:04 AM
Bristol-Myers Squibb (BMY) Snaps Up Private Cancer Drugmaker in $1.25 Billion Buyout 2/23/2015 6:57:05 AM
Rigel (RIGL) Lands $339 Million+ Cancer Deal With Bristol-Myers Squibb (BMY) 2/23/2015 6:38:33 AM
Best Hair in Biopharma Race Heats Up As Bristol-Myers Squibb (BMY) Elicker Pulls Ahead 2/19/2015 11:23:04 AM
FDA Approves Bristol-Myers Squibb Company (BMY)’s Evotaz™ (Atazanavir And Cobicistat) For The Treatment Of HIV-1 Infection In Adults 1/30/2015 6:06:45 AM
12345678910...